The chances of the Pacific bluefin tuna stock meeting an international recovery target of around 40,000 tons by 2024 was placed at 100 percent.
According to the latest assessment by the International Scientific Committee for Tuna and Tuna-like Species in the North Pacific Ocean, even if each member of the northern committee expands its catch quota by 10 percent, the chances of making the target remain 100 percent.
If expanded by 20 percent, there would still be a 99 percent probability.
There are concerns over the depletion of the Pacific bluefin tuna, a popular fish for sushi, but the assessment could set the stage for quota expansion discussions.
Japan has been pursuing an expansion of catch quota at meetings of the Northern Committee of the Western and Central Pacific Fisheries Commission, which includes South Korea, the United States, Canada, Taiwan, and China.
But parties like the United States opposed quota expansions as the tuna has not recovered enough.
From its peak of 156,000 tons in 1961, the stock declined to a historically low level of 11,000 tons in 2010.
The stock recovered to an estimated 28,000 tons in 2018.
After the restrictions were introduced in 2015, Japan once exceeded its annual quota through June 2017.


Google Secures Pentagon AI Deal for Classified Projects
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 



